Polihexanide
CAS 32289-58-0
Polihexanide (CAS 32289-58-0) is a pharmaceutical compound with 0 bioactivity targets and 75 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| POLYAMINOPROPYL BIGUANIDE | 1314381 | SU | MTHSPL |
| POLIHEXANIDE | 1373041 | SU | MTHSPL |
| polihexanide | 1373041 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Polihexanide used for in pharmaceutical contexts?
Polihexanide (CAS 32289-58-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Polihexanide?
Polihexanide has 75 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Anaemia, Anterior chamber inflammation, Blood lactate dehydrogenase increased, Corneal epithelium defect, Corneal oedema. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Polihexanide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Polyaminopropyl Biguanide with EU status "restricted".
What clinical phase is Polihexanide in?
No phase 1-4 clinical development badge is rendered for Polihexanide because the matched compound identifier rows do not contain a max-phase value.